8-K: Fulgent Genetics Reports Mixed Q2 Results, Core Revenue Up 5% Year-Over-Year

Fulgent Genetics announced its Q2 2024 financial results, showing a 5% year-over-year growth in core revenue to $70.2 million, while also reporting a GAAP loss of $8.7 million.

Summary

• Fulgent Genetics reported a total revenue of $71.0 million for the second quarter of 2024.
• Core revenue, excluding COVID-19 testing, grew by 5% year-over-year to $70.2 million.
• The company experienced a GAAP loss of $8.7 million, or ($0.29) per share.
• Non-GAAP income was $4.7 million, or $0.15 per share.
• Adjusted EBITDA showed a loss of $727,000.
• Cash from operations was $4.3 million.
• The company held $837.9 million in cash, cash equivalents, and marketable securities as of June 30, 2024.
• Fulgent has reiterated its full-year 2024 core revenue guidance of $280 million.
• The company has improved its full-year 2024 earnings per share guidance, with GAAP loss per share expected to improve from approximately ($2.25) to ($1.95) and non-GAAP loss per share expected to improve from approximately ($1.05) to ($0.30).
• Fulgent anticipates having approximately $800 million in cash, cash equivalents, and investments in marketable securities by the end of 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the core revenue growth, improved earnings guidance, and progress in therapeutic development, but tempered by the GAAP loss and negative EBITDA. The company's strong cash position and strategic vision are also positive factors.

Positives

• The company's core revenue is growing, indicating strength in its laboratory services business.
• Fulgent has a substantial cash position, providing financial flexibility.
• The company is making progress in its therapeutic development programs, with a Phase 2 trial underway and another candidate advancing towards an IND application.
• The company has improved its earnings per share guidance for the full year 2024.
• Fulgent's proprietary technology platform allows for rapid scaling of a broad, flexible test menu.
• The company has a history of successfully scaling operations, as demonstrated by its response to the COVID-19 pandemic.

Negatives

• The company reported a GAAP loss of $8.7 million for the quarter.
• Adjusted EBITDA was negative at $727,000.
• The company is still experiencing losses, although they are improving.
• Cash from operations was only $4.3 million for the quarter.

Risks

• The market potential for the company's tests and the rate of market adoption are uncertain.
• The company's ability to maintain turnaround times and keep pace with rapidly changing technology is a risk.
• The company's success in obtaining coverage and adequate reimbursement from third-party payors is not guaranteed.
• The company's research and development efforts, including clinical trials, are subject to risks and uncertainties.
• The company's customer base can fluctuate, and a small number of customers may account for a significant portion of revenue.
• Cash expenditures may be higher or lower than currently estimated due to a variety of factors and circumstances, including as a result of the company's ongoing stock repurchase program or other expenditures outside the ordinary course of business.

Future Outlook

Fulgent expects full-year 2024 core revenue of approximately $280 million, with improved GAAP loss per share to approximately ($1.95) and non-GAAP loss per share to approximately ($0.30). The company also anticipates having approximately $800 million in cash, cash equivalents, and investments in marketable securities by the end of 2024.

Management Comments

• Ming Hsieh, Chairperson and CEO, stated that Laboratory Services continue to be a source of strength for Fulgent, with momentum in Precision Diagnostics.
• Ming Hsieh also noted that the company is off to a good start with initial enrollment of the Phase 2 trial of FID-007 and is moving FID-022 towards an IND application.
• Paul Kim, CFO, said that the company continues to be on track with operational objectives set at the beginning of 2024 and remains in an enviable cash position.

Industry Context

The announcement reflects the ongoing shift in the diagnostics industry towards precision medicine and the integration of therapeutic development. Fulgent's focus on oncology and its efforts to combine diagnostics and therapeutics align with broader industry trends. The company's acquisition of Inform Diagnostics and CSI Laboratories, along with its therapeutic development efforts, position it to compete in the evolving landscape of cancer care.

Comparison to Industry Standards

• Fulgent's 5% core revenue growth is a positive sign, but it is important to compare this to the growth rates of other genetic testing companies such as Exact Sciences, which has seen significant growth in its core business.
• The company's GAAP loss of $8.7 million is not unusual for a company investing heavily in R&D, but it is important to compare this to the profitability of more established players like Quest Diagnostics or LabCorp.
• Fulgent's cash position of $837.9 million is strong compared to many smaller biotech companies, but it is important to consider how this cash is being deployed and whether it is generating sufficient returns.
• The company's progress in its therapeutic pipeline, particularly with FID-007, is promising, but it is still early stage compared to companies with more advanced clinical programs such as Amgen or Gilead.
• Fulgent's focus on a vertically integrated solution for cancer care is similar to the strategies of companies like Roche, which has a strong presence in both diagnostics and therapeutics.

Stakeholder Impact

• Shareholders may be encouraged by the core revenue growth and improved earnings guidance, but concerned about the GAAP loss.
• Employees may be impacted by the company's strategic direction and growth initiatives.
• Customers may benefit from the company's expanded test menu and therapeutic offerings.
• Suppliers may see increased business opportunities as the company grows.
• Creditors may be reassured by the company's strong cash position.

Next Steps

• Continue enrollment in the Phase 2 trial of FID-007 in Head and Neck Cancer.
• Advance FID-022 through preclinical studies towards an IND application by the end of 2024.
• Execute on the company's growth strategy, including organic and inorganic initiatives.
• Continue to manage cash expenditures and the stock repurchase program.

Key Dates

Keywords

Genetics, Diagnostics, Therapeutics, Precision Medicine, Laboratory Services, Oncology, NGS, Drug Development, FID-007, FID-022, Clinical Trials